Ophthalmologic toxicities of antineoplastic agents in genitourinary cancers: Mechanisms, management, and clinical implications
Open Access
- 20 December 2024
- journal article
- research article
- Published by Elsevier in Current Problems in Cancer
- Vol. 54, 101171
Abstract
No abstract availableKeywords
This publication has 241 references indexed in Scilit:
- Risk of Ocular Adverse Events With Taxane-Based ChemotherapyJAMA Ophthalmology, 2022
- Fibroblast Growth Factor Receptor Inhibitor–Associated RetinopathyJAMA Ophthalmology, 2020
- Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal VenulitisJAMA Ophthalmology, 2019
- Birdshot-like Chorioretinopathy Associated With Pembrolizumab TreatmentJAMA Ophthalmology, 2018
- Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal DetachmentJAMA Ophthalmology, 2017
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaJAMA Oncology, 2017
- Clinical Spectrum of Reversible Posterior Leukoencephalopathy SyndromeArchives of Neurology, 2008
- Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tractCancer, 2000
- Retinal toxicity associated with cisplatin and etoposide in pediatric patientsMedical and Pediatric Oncology, 1997
- Ocular toxicity and cancer chemotherapy: A reviewCancer, 1996